I. INTRODUCTION
The development of drug delivery systems has improved the therapeutic and toxicological properties of existing chemotherapeutic agents and fostered the implementation of new ones. By encapsulating the drug within technologically optimized drug delivery systems or conjugating the drugs with different polymers, it is possible to modify the drug's pharmacokinetics and biodistribution, improving the efficacy and security of the therapy. 1 Among the new drug delivery systems, nanocapsules have been defined as vesicular systems in which the drug is confined to a cavity surrounded by an unique polymer membrane. This reservoir can be either hydrophilic or hydrophobic according to the preparation method and the raw materials used. 2 The role of selenium (Se) as an antioxidant and anticancer agent is very well documented in the literature. 3 In addition, it has been proved that ideal concentration of selenium can restore the sensitivity for chemotherapeutic agent of cytostatic-resistant malignant cells. Selol is a mixture of selenitetriglycerides synthesized from sunflower oil. 4 Selol contains Se 4þ in its structure and, exhibits chemopreventive and anticancer activity. 5 Another therapy that has been used for cancer treatment is hyperthermia, which is a very promising approach. 6, 7 It is thought that thermal tissue sensitization (using hyperthermia for site heating up to 45 C) leads to changes on the function of many structural and enzymatic proteins within cells, which, in turn, alters cell growth and differentiation and can induce apoptosis. 8 Thermal ablation (site heating above 45 C) usually induces necrosis instead. 9 Furthermore, the principle of magnetic site localization of magnetic drug delivery systems is based on submicron host particles encapsulating simultaneously magnetic nanoparticles and drug molecules. When the carrying particles enter the bloodstream, external gradients of magnetic fields are used to concentrate them at a specific target site within the body. 10 Magnetic nanoparticles have been used to deliver hyperthermia, and they may be of different chemical compositions. Iron oxide particles, such as magnetite (Fe 3 O 4 ) or its oxidized (and hence more stable) form maghemite (c-Fe 2 O 3 ) are by far the most commonly employed magnetic oxides for biomedical applications.
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The main goal of this study was to develop a polymeric drug delivery system loaded and unloaded with nanosized maghemite plus Selol. The resulting formulations were characterized for size, morphology, charge, and stability. In vitro antitumor activity of the formulations was evaluated using metastatic murine melanoma cell line (B16-F10). 
II. EXPERIMENTAL
Selol (5% Se) was provided by the Department of Drugs Analysis from the Warsaw Medical University (Warsaw, Poland). Poly (DL-lactic-co-glycolic acid) (PLGA) 50:50 polymer and poloxamer 188 were purchased from Sigma (Sigma-Aldrich, Co., St. Louis, MO). Soy phosphatidylcholine was obtained from Gerbras (Gerbras, Brazil). Acetone was purchased from J.T. Baker (Mallinckrodt Baker, Phillipsburg). Maghemite (c -Fe 2 O 3 ) nanoparticles (8.9 6 0.1 nm in diameter; mean 6 SD), suspended as an ionic magnetic fluid and stabilized at low-pH aqueous medium, was used to obtain the nanostructured magnetic drug delivery system, as previously described. 12 Ultrapure water was obtained from E-pure apparatus (Barnstead, IA).
The polymeric nanocapsules were prepared according to a modified precipitation method. 13 Briefly, in the first step, PLGA polymer, soy phosphatidylcholine and Selol were dissolved in acetone at 40 C. The as prepared organic phase was added dropwise under stirring into an aqueous phase containing the poloxamer 188 and the ionic fluid (added in the preparation of the magnetic nanocapsule). Organic solvent was removed out from the medium by evaporation under reduced pressure at 40 C. Finally, the formulations were concentrated to a final volume of 10 ml. Drug-free nanocapsules were prepared according the same procedure.
Particle size distribution (mean diameter and size dispersity) was determined by photon correlation spectroscopy (PCS) at a scattering angle of 173 and at 25 C, using the Zetasizer V R (Nano-ZS, Malvern Instruments). Zeta potential was measured by electrophoretic mobility using the same Zetasizer system. The analysis was performed using samples diluted with ultrapurified water. Data provided in Table I represent the mean (6SD) of three different batches of each nanocapsule formulation. The morphology of the loaded nanoparticles was analyzed using transmission electron microscopy (TEM) (CM-120, Philips, The Netherlands). For TEM observation, the nanoparticle suspensions were diluted in deionized water and sonicated for 20 min. A drop of the suspension was placed onto a carbon-coated copper grid and dried for 24 h before the analysis. The effect of the storage time on the particle size and zeta potential of the nanocapsules was assessed. Nanocapsule aqueous dispersions were stored in sealed glass bottles at 4 C, during a period of 3 months.
Metastatic murine B16-F10 melanoma cell line was obtained from American Type Culture Collection (ATCC, Manassas, VA). The cellular culture was accomplished as described by Barbugli et al.
14 The cells were treated with five formulations (1 ¼ drug-free nanocapsule þ ionic magnetic fluid at 5 Â 10 9 particle/ml; 2 ¼ Selol-loaded nanocapsules at 100 lg/ml; 3 ¼ Selol-loaded nanocapsule at 25 lg/ ml þ ionic magnetic fluid at 1.25 Â 10 9 particle/ml; 4 ¼ Selolloaded nanocapsule at 50 lg/ml þ ionic magnetic fluid at 2.5 Â 10 9 particle/ml; and 5 ¼ Selol-loaded nanocapsule at 100 lg/ml þ ionic magnetic fluid at 5 Â 10 9 particle/ml) for 3 h in an incubator (5% CO 2 , 37 C, humidified atmosphere). Subsequently, the medium with formulations was removed. 
FIG. 2. Evolution of mean size (A)
and zeta potential (B) of drug-free nanocapsules *; Selol-loaded nanocapsules n; drug-free nanocapsules þ ionic magnetic fluid n; Selol-loaded nanocapsules þ ionic magnetic fluid n, during storage at 4 C for up to 3 months.
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Then, cells were rinsed with Hank's buffer, and medium was added in each well for 24 h. The effect of the different treatments on cell viability was assessed by the tetrazolium dye assay (MTT), as previously described by Mosmannl. 15 
III. RESULTS AND DISCUSSION
The nanocapsule's physicochemical properties, in terms of their mean diameter, size dispersity, morphology, and zeta potential, were evaluated (see Table I ). With respect to the particle size analysis, as illustrated in Table I , all systems prepared were in the nanosize range (mean diameter < 240 nm) and exhibited a narrow size distribution (polydispersity index < 0.267). The Selol-loaded nanocapsules þ ionic magnetic fluid exhibited an increase in the mean diameter in comparison with the other formulations. All formulations exhibited a negative charge with zeta potential values ranging from À54.4 to À26.8 mV. A minimal reduction in this parameter was observed when the ionic magnetic fluid was used.
Representative TEM micrographs obtained are presented in Fig. 1 . Figure 1(a) shows spherically shaped nanocapsules as well as their homogeneous particle size distribution. The TEM image in Fig. 1(b) clearly demonstrates the nanosized magnetic particles incorporated within the PLGA nanosized template.
As shown in Fig. 2(a) , no significant differences on the mean size and zeta potential of nanocapsules were observed during storage of the respective aqueous dispersions at 4 C for up to 3 months.
The cytotoxic activity of the Selol/ionic magnetic fluid loaded and unloaded nanocapsules was evaluated by the MTT assay using B16-F10. Data presented on Fig. 3 show a remarkable variation in the cell viability (up to 50%). This result was pronounced when B16-F10 cells were incubated with Selol-loaded nanocapsule at 100 lg/ml þ ionic magnetic fluid at 5 Â 10 9 particle/ml. 5 The Selol entrapment within the nanosized template shows an effective anticarcinogenic potential and promising applicability as a nanostructured drug delivery system. The association with magnetic nanoparticles shows appropriate biocompatibility and can be useful for the synergistic action involving drug delivery and hyperthermia for cancer treatment.
IV. CONCLUSIONS
The results of this study showed that Selol-loaded magnetic nanocapsules were successfully prepared by the precipitation method. The nanosized samples revealed suitable physicochemical stability while shelved for up to 3 months after preparation. The light scattering and TEM analyzes showed a nanostructured material with ideal properties for use as a platform in nanotechnology. Besides, the biological assays demonstrated the important antineoplastic effect after incubation with melanoma cells. Therefore, the results lead to the proposal of a new nanocarrier for encapsulation of Selol and magnetic nanoparticles, which will be evaluated in the near future in regard to its application to cancer treatment based in magnetic field application (hyperthermia) and cancer therapy.
